Neuroblastoma: Biology and Therapy

ONCOLOGY

Volumn 11, Issue 12, 1997, Pages 1857-1866

  Matthay, Katherine K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANIMAL; CLINICAL TRIAL; GENETIC MARKER; GENETICS; HUMAN; MASS SCREENING; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR;

ANIMALS; CLINICAL TRIALS; GENETIC MARKERS; HUMANS; MASS SCREENING; MICE; NEUROBLASTOMA; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031310886     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Fong C, Dracopoli NC, White PS et al: Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification. Proc Natl Acad Sci USA 86:3753-3757, 1989
2. Matthay KK: Neuroblastoma in, Pochedly C (ed): Neoplastic Diseases in Childhood, pp 725-768. Chur, Switzerland, Harwood Academic, 1994.
3. Suzuki T, Yokota J, Mugishima H, et al: Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 49:1095-1098, 1989.
4. Plantaz D, Mohapatra G, Matthay KK, et al: Gain of the chromosome 17 is the most frequent abnormality detected in neuroblastoma by CGH. Am J Pathol 150:1-9, 1997.
5. Seeger RC. Brodeur GM, Sather H, et al Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas N Engl J Med 313.1111-1116, 1985.
6. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993.
7. Crabbe DCG, Peters J, Seeger RC: Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diag Mol Path 1:229-234, 1993.
8. Look AT, Hayes FA, Schuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:581-591, 1991.
9. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high affinity nerve growth factor receptors in aggressive neuroblastomas J Natl Cancer Inst 85:377-384, 1993.
10. Hiyama E, Hiyama K, Yokoyama T, et al: Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1(3):249-255, 1995.
11. Reynolds CP, Zuo JJ, Wang H, et al: Telomerase in primary neuroblastomas. Prog Clin Biol Res, 1997 (in press).
12. Shimada H, Stram DO, Chatten J, et al: Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470-1476, 1995.
13. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. Hum Pathol 19:1187-1198, 1988.
14. Haase GM, O'Leary MC, Stram DO, et al: Pelvic neuroblastoma: Implications for a new favorable subgroup: A Childrens Cancer Group experience. Ann Surg Oncol 2:516-523, 1995.
15. Matthay KK, Sather HN, Seeger RC, et al: Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 7.236-244, 1989.
16. Matthay K, Seeger R, Haase G, et al: Treatment and outcome for stage III neuroblastoma based on prospective biologic staging. Med Pediatr Oncol 23:173, 1994.
17. Matthay KK, Lukens J, Stram D, et al. Prognosis for stage IV neuroblastoma less than one year at diagnosis: A prospective Childrens Cancer Group Study. Proc Am Soc Clin Oncol 14:446, 1995.
18. Stram DO, Matthay KK, O'Leary M, et al: Consolidation chemoradiotherapy and autologous bone marrow transplantation vs continued chemotherapy for metastatic neuroblastoma: A report of two concurrent Children's Cancer Group studies. J Clin Oncol 14:2417-2426, 1996.
19. Brodeur GM, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988.
20. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993.
21. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991.
22. Matthay KK, Reynolds CP, Stram DO, et al: Quantitative tumor cell content of bone marrow and blood as an early predictor of response in high risk neuroblastoma. A CCG study (abstraact 1844). Proc Am Soc Clin Oncol 16:512a, 1997.
23. Haase GM, Atkinson JB, Stram DO, et al: Surgical management and outcome in non-metastatic neuroblastoma: Comparison of the Childrens Cancer Group and the International Staging Systems. J Pediatr Surg 30:289-295, 1995.
24. Matthay K, Lukens J, Stram D, et al: Improving survival from 1978-1995 using risk based treatment for neuroblastoma: Children's Cancer Group (CCG). Med Pediatr Oncol 27:220, 1996.
25. Cheung NKV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1050-1058, 1991.
26. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991.
27. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2230-2341, 1993.
28. Kushner BH, O'Reilly RJ, Mandell LR, et al Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991.
29. Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic vs autologous purged bone marrow transplantation for neuroblastoma. J Clin Oncol 12:2382-2389, 1994.
30. Matthay KK, Stram DO, Selch ME, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group Study J Clin Oncol 11:2226-2233, 1993.
31. Ohnuma N, Takahashi H, Kaneko M, et al: Treatment combined with bone marrow transplantation for advanced neuroblastoma: An analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan. Med Pediatr Oncol 24:181-187, 1995.
32. Pinkerton CR. ENSG 1 randomized study of high-dose melphalan in neuroblastoma. Bone Marrow Transplant 3(suppl):112-113, 1991.
33. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1031-1044, 1991
34. Schuster JJ, Cantor AB, McWilliams N, et al: The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 9:1045-1049, 1991.
35. Kalra R, Zoger S, Matthay KK: Miliary spread of neuroblastoma: Radiological case of the month. Arch Pediatr Adolesc Med 149:194-195, 1995.
36. Rill DR, Santana VM, Roberts M, et al: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells Blood 84:380-383, 1994.
37. Reynolds CP, Seeger RC, Vo DD, et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46:5882-5886, 1986.
38. Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the ChildrenÕs Cancer Group. Cancer 80:317-33, 1997.
39. Handgretinger R, Anderson K, Lang P, et al: A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261-267, 1995.
40. Yu AL, Batova A, Avarado C, et al: Usefulness of a chimeric anti-GD2 (Ch 14-18) and GM-CSF for refractory neuroblastoma: A POG phase II study (abstract). Proc Am Soc Clin Oncol 16:513a, 1997.
41. Cheung NK, Kushner BH, Yeh SJ, et al: 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma. A phase II study. Prog Clin Biol Res 385:319-328, 1994.
42. 131I-metaiodo-benzylguanidine (MIBG) with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol in press, 1997.
43. Villablanca JG, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 134:894-901, 1995.
44. Reynolds CP, Kane DJ, Einhorn PA, et al: Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 366:203-211, 1991.
45. Finklestein JZ, Krailo MD, Lenarsky C, et al: 13-Cis-retinoic acid in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med Pediatr Oncol 20:307-311, 1992.